Yesterday I received the interesting Linda Pullan's newsletter (I recommend you to subscribe at her website) with some interesting and meaningful data on mergers and acquisitions in the biotech industry. I
think it worth sharing as the data shows a significant activity for the
first half of the year.
The M&A activity in the 1st half of 2015 is not as frenzied as last years, but is active.
EvaluatePharma
The M&A activity in the 1st half of 2015 is not as frenzied as last years, but is active.
|
M&A Trends:
1. Rare diseases. Among the leaders in 2Q 2015 was Alexion in the big trend of rare disease companies needing to buy or be bought.
2. Specialty and generics.
Actavis (now called Allergan) has been the biggest spender in M&A
for the last few years and just gobbled up Kythera, the So Cal derm
company led by ex-Amgen folks. Reflecting the roll-up of specialty and
generic firms, Valeant is 2nd most active over the last few years. 3. Some big pharma but not others are M&A driven.
| The industry's big spenders - three-year M&A bill | |||
| Big pharma | |||
| Company | 3yr spend ($bn) | 3yr deal count | M&A ranking |
| Pfizer | 19.3 | 8 | 3 |
| Novartis | 17.8 | 10 | 4 |
| AbbVie | 17.6 | 1 | 6 |
| Merck & Co | 13.8 | 4 | 9 |
| Roche | 11.9 | 7 | 10 |
| Total 10 big pharma | 93.8 | 65 | |
| Other big drug makers (market cap ≥$20bn) | |||
| Company | 3yr spend ($bn) | 3yr deal count | M&A ranking |
| Allergan | 112.3 | 10 | 1 |
| Valeant Pharmaceuticals | 24.6 | 9 | 2 |
| Bayer | 17.7 | 4 | 5 |
| Perrigo Company | 14.7 | 8 | 7 |
| Endo International | 14.6 | 8 | 8 |
| Total 88 non-big pharma | 299.5 | 240 |
